Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

VIVS vs MRNA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MRNA Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 9–1 Matrix Metrics)

MRNA Overall Winner 6-Pillar Tally: VIVS 1 – 5 MRNA Matrix Metrics: VIVS 1 – 9 MRNA

As of Nov 19, 2026, Moderna, Inc. (MRNA) is the stronger overall head-to-head candidate over VivoSim Labs, Inc. (VIVS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VIVS carries a Unified Composite Score of 39.0/100 (SELL) at $0.29 (N/M Forward P/E, -10117.0% operating margin), whereas MRNA carries 39.5/100 (SELL) at $199.33 (23.0x Forward P/E, -80.8% operating margin).

  • Defensive Composite Rating Caution: Although MRNA compares more favorably head-to-head, both VIVS (39.0/100 SELL) and MRNA (39.5/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: VIVS is currently in a Breakdown options structure phase (RSI 75.1); meanwhile MRNA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 42.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VIVS vs MRNA
VIVS NASDAQ
VivoSim Labs, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.29
+142.92% 1D
Market Cap $2.4M
TTM Revenue $112,000
Forward P/E N/M
Beta / 30D Vol 0.83β · 480% Vol
Unified Composite Score
39.0 / 100 SELL
Tech 5.0 Fund 47.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 75
RSI-14: 75.1 · SMA20: $0.15 · SMA50: $0.18
MRNA NASDAQ Head-to-Head Winner
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$199.33
+1.29% 1D
Market Cap $79.6B
TTM Revenue $2.52B
Forward P/E 23.0x
Beta / 30D Vol 2.31β · 97% Vol
Unified Composite Score
39.5 / 100 SELL
Tech 15.0 Fund 42.0 Flow 68.0 Mom 46.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 43
RSI-14: 42.8 · SMA20: $225.51 · SMA50: $206.87

6-Pillar Scorecard Institutional Category Breakdown (VIVS 1 – 5 MRNA)

Columns: Metric · VIVS · MRNA
1. Valuation Multiples MRNA
Forward P/E N/M 23.0x
Trailing P/E N/M 23.0x
PEG Ratio N/M N/M
EV / Revenue 9.6x 32.7x
2. Growth & Scale MRNA
Revenue Growth (YoY) -51.4% +29.2%
Earnings Growth (YoY) +0.0% -85.1%
TTM Revenue (USD) $112,000 $2.52B
Market Cap $2.4M $79.6B
3. Profitability & Quality MRNA
Gross Margin N/A -42.0%
Operating Margin -10117.0% -80.8%
Net Profit Margin 0.0% -110.5%
Return on Equity (ROE) -343.1% -34.5%
4. Balance Sheet & Cash Flow VIVS
Cash Generation (TTM) -$11M EBITDA -$2.04B
Cash Flow Margin N/A -81.0%
Net Cash / Leverage $1.4M Net Cash $3.03B Net Debt (0.62x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MRNA
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile N/A (N/A) 97.2% (61st %ile)
Put/Call OI Skew N/A 1.30x (Put-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Neutral DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat MRNA
OpEx & R&D Intensity N/A 38.8% of Rev ($980M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VIVS (1) vs MRNA (9)
Institutional Metric VIVS MRNA Criterion Row Edge
Market Capitalization
Scale
$2.4M $79.6B Larger Scale MRNA
Trailing P/E Ratio
Valuation
N/M 23.0x Lower Multiple MRNA
Forward P/E Ratio
Valuation
N/M 23.0x Lower Multiple MRNA
Revenue Growth (YoY)
Growth
-51.4% +29.2% Higher Growth MRNA
Operating Margin (TTM)
Profitability
-10117.0% -80.8% Higher Margin MRNA
Net Profit Margin
Profitability
0.0% -110.5% Higher Margin VIVS
Return on Equity (ROE)
Capital Efficiency
-343.1% -34.5% Higher ROE MRNA
52-Week Range Position
Momentum
5% ($0–$3) 68% ($22–$281) Stronger Trend MRNA
Beta / 30D Volatility
Risk Regime
0.83β · 480% Vol 2.31β · 97% Vol Lower Realized Risk MRNA
Unified Institutional Score
Composite Signal
39.0 / 100 (SELL) 39.5 / 100 (SELL) Higher Composite MRNA
Trailing 12M Revenue (USD)
Operating Scale
$112,000 $2.52B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A -42.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 9.6x EV/Rev N/M PEG · 32.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$11M EBITDA ($1.4M Net Cash) -$2.04B ($3.03B Net Debt (0.62x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VIVS +83.6 pp
VIVS: +64.69% · MRNA: -18.91%
3M Horizon MRNA +35.43 pp
VIVS: +1.92% · MRNA: +37.35%
6M Horizon MRNA +400.02 pp
VIVS: -78.25% · MRNA: +321.77%
1Y Horizon MRNA +786.87 pp
VIVS: -86.99% · MRNA: +699.88%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period VIVS Revenue MRNA Revenue VIVS Op. Margin MRNA Op. Margin Margin Leader
FY2019 $0M $60M -882.4% -906.8% VIVS
FY2020 $0M $800M -977.9% -95.0% MRNA
FY2021 N/A $18.5B N/A 72.0% MRNA
FY2022 $0M $19.3B -765.3% 48.9% MRNA
FY2023 $0M $6.85B -4792.2% -61.9% MRNA
FY2024 $0M $3.24B -13840.4% -121.9% MRNA
FY2025 $0M $1.94B -8761.1% -158.1% MRNA
FY2026 $0M N/A -8768.7% N/A VIVS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VIVS BREAKDOWN
73d in phase · OBV ACCUMULATION
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact VIVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MRNA CONSOLIDATION
21d in phase · OBV DISTRIBUTION
Current IV 97.2%
IV Percentile 61st %ile
Put/Call OI Skew 1.30x (Put-Skewed)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact MRNA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $215.27 · IV 83.7%

MRNA Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($21,527)

Compare $21,527 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 83.7% ATM IV.

5-DAY BULLISH SWING Liq A

Dec 18 $220 / $260 Bull Call Spread

Buy 1x $220C · Sell 1x $260C · 32d

Net Entry $1,105 Debit
T+5d @ +5% Move +$267 (+24%)
Max Risk / Buffer $1,105 Capped
5d Edge & Liquidity 0.7x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $190 / $180 Bull Put Spread

Sell 1x $190P · Buy 1x $180P · 32d

Net Entry $255 Credit
Max Credit / Yield +$255 (+34.2% RoM)
Max Risk / Buffer -12.9% Cushion ($745 Mgn)
5d Edge & Liquidity 74% PoP · Liq A
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq A

Dec 18 $190P / $220-$260C Seagull

Sell 1x $190P · Buy 1x $220/$260C · 32d

Net Entry $140 Debit
T+5d @ +5% Move +$693 (+23.1% RoM)
Max Risk / Buffer -11.7% Put Cushion ($3,005 Mgn)
5d Edge & Liquidity 1.1x R:R · Liq A
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VIVS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.4M market capitalization and -10117.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MRNA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $79.6B market capitalization and -80.8% operating margin.
OpEx & R&D Reinvestment 38.8% of Rev ($980M)
90D Engineering Disclosures 0 Published · mRNA Therapeutics

Investor FAQ VIVS vs MRNA Key Questions & Quantitative Answers

As of Nov 19, 2026, Moderna, Inc. (MRNA) is the stronger overall head-to-head candidate over VivoSim Labs, Inc. (VIVS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VIVS carries a Unified Composite Score of 39.0/100 (SELL) at $0.29 (N/M Forward P/E, -10117.0% operating margin), whereas MRNA carries 39.5/100 (SELL) at $199.33 (23.0x Forward P/E, -80.8% operating margin). Defensive Composite Rating Caution: Although MRNA compares more favorably head-to-head, both VIVS (39.0/100 SELL) and MRNA (39.5/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: VIVS is currently in a Breakdown options structure phase (RSI 75.1); meanwhile MRNA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 42.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MRNA leads the Growth & Scale pillar: VIVS posts -51.4% YoY revenue growth and +0.0% YoY earnings growth on $112,000 TTM revenue (N/A gross margin, -10117.0% operating margin), compared with MRNA at +29.2% YoY revenue growth and -85.1% YoY earnings growth on $2.52B TTM revenue (-42.0% gross margin, -80.8% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), VIVS cumulative revenue shifted N/A while MRNA shifted +3133.3%. In operating R&D and SG&A reinvestment, VIVS deploys N/A (0 90-day corporate R&D disclosures) versus 38.8% of Rev ($980M) (0 disclosures) for MRNA.

MRNA screens cheaper on headline valuation multiples. VIVS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.6x EV/Revenue (unreported EBITDA margin), whereas MRNA trades at 23.0x Forward P/E, 23.0x Trailing P/E, N/M PEG, and 32.7x EV/Revenue (-81.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VIVS (-343.1% ROE) versus MRNA (-34.5% ROE) capital efficiency.

In options market volatility and institutional positioning, VIVS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.83β · 480% Vol realized risk). By comparison, MRNA carries 97.2% implied volatility (61st %ile, Elevated (60th–80th %ile)), a 1.30x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (2.31β · 97% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.